1360802-78-3Relevant articles and documents
CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins
Bard, Jonathan A.,Brown, Christopher J.,Chen, Xuemei,Clark-Frew, Daniel,Coe, Samuel,Conlon, Mike,Davis, Randall,Dominguez, Celia,Ensor, Samantha,Esposito, Simone,Gai, Xinjie,Green, Samantha,Greenaway, Catherine,Haber, James,Halldin, Christer,Hayes, Sarah,He?mann, Manuela,Herbst, Todd,Herrmann, Frank,Hsai, Ming Min,Johnson, Peter D.,Khetarpal, Vinod,Kotey, Adrian,Lee, Matthew R.,Liu, Longbin,Mangette, John E.,Mills, Matthew R.,Monteagudo, Edith,Moren, Anton Forsberg,Mrzljak, Ladislav,Munoz-Sanjuan, Ignacio,Nag, Sangram,Nibbio, Martina,Orsatti, Laura,Prime, Michael E.,Schaertl, Sabine,Scheich, Christoph,Sproston, Joanne,Stepanov, Vladimir,Varn?s, Katarina,Varrone, Andrea,Wityak, John
, p. 12003 - 12021 (2021/09/02)
The expanded polyglutamine-containing mutant huntingtin (mHTT) protein is implicated in neuronal degeneration of medium spiny neurons in Huntington's disease (HD) for which multiple therapeutic approaches are currently being evaluated to eliminate or redu
SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS
-
Page/Page column 70-71, (2012/03/11)
Described herein are compounds of formula I. The compounds of formula I act as DGAT-1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.